Celebrating Summer at Sonata Therapeutics! At Sonata, we believe in fostering a vibrant team culture, and our recent summer outing was a testament to just that! 🎉 Yesterday our team and their families came together for an afternoon filled with fun, laughter, and bonding. From competitive games to delicious food, it was a time to remember. Our outing not only strengthened friendships but also reinforced our commitment to collaboration and innovation. A huge shout-out to our culture commitment team who helped organize this fantastic event and making it such a success. Here's to more memorable moments ahead at Sonata! #TeamBuilding #CompanyCulture #SummerOuting #Sonata #WorkHardPlayHard
About us
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20 billion in aggregate value, 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.
- Website
-
http://www.SonataTX.com
External link for Sonata Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, Massachusetts
- Type
- Privately Held
- Specialties
- Drug Discovery, Cell Signaling, Cell Microenvironment, Small Molecule, Cell Therapy, Gene Therapy, mRNA, Immuno-Oncology, and Genetic Platform
Locations
-
Primary
Get directions
500 Arsenal Street
Watertown, Massachusetts 02472, US
Employees at Sonata Therapeutics
-
Michael Crescenzi
Vice President, Strategy, Corporate Development & Operations at Sonata Therapeutics
-
Pete Gough
-
Nadia Gurvich
Director, Oncology I Immuno-Oncology I Preclinical Pharmacology I Translational Medicine I Drug Development
-
Erik Hett
Chief Technology Officer at Sonata Therapeutics | Innovative leader in drug discovery
Updates
-
Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be part of the #FlagshipFounded ecosystem of companies making #biggerleaps for patients.
Flagship Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship Founder and CEO Noubar Afeyan about how we're taking #BiggerLeaps by leveraging the power of generative AI, forging novel partnerships with pharma to speed drug development, expanding globally, and promoting and hiring top talent to our leadership ranks. Read the full press release: https://bit.ly/4eQfx05
-
The Champalimaud Centre is one of Europe’s leading oncology research institutes and Sonata Therapeutics is excited to be working with them to translate the immense potential of our Network Medicine SNT-3012 to the clinic. Sonata’s scientific leaders had the opportunity to strategize with the team, review data and see firsthand how SNT-3012 transforms the tumor microenvironment, resulting in the broad activation of human tumor-specific T cells. Sonata looks forward to continuing this important collaboration with Champalimaud to bridge the gap between basic science and clinical application and rapidly bring SNT-3012 to cancer patients in need.
-
-
Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below.
Swipe through our newest Flagship Flashcards to learn how #FlagshipFounded companies are pioneering new science including somatic genomics (Quotient Therapeutics), genetic chemistry (Empress Therapeutics), and Network Medicines™ (Sonata Therapeutics) to advance the discovery and development of novel therapeutics. Flip through more Flagship Flashcards: https://bit.ly/3FI16LQ
-
Our team had an exciting and productive time at #AACR24. Not only was it great to connect with global #cancer leaders and hear about all of the new research being done to cure patients of cancer, but it was also rewarding to see how our differentiated Network Medicines may address many of the key issues in cancer therapy that we are all trying to tackle. Already looking forward to next year
-
-
We're pleased to announce a research collaboration with the Champalimaud Foundation for the development of SNT-3012 in pancreatic and colorectal cancers. Read more: https://lnkd.in/eeVRji26 #CancerResearch #Cancer #Health #research
-
-
Sonata Therapeutics reposted this
Hear from the CEOs and leaders of #FlagshipFounded companies as they share the latest platform and pipeline updates, the therapeutic areas they’re focused on, new & expanded partnerships, how they’re building company culture, and what’s ahead for 2024. Watch all the latest CEO Chats here: bit.ly/48LWm3t 🔹 Fabrice Chouraqui, CEO, Cellarity 🔹 Steve Harr, CEO, Sana Biotechnology, Inc. 🔹 Volker Herrmann, MD, CEO, Sonata Therapeutics 🔹 John Lepore, CEO, ProFound Therapeutics 🔹 Michael Nally, CEO, Generate:Biomedicines 🔹 Guillaume Pfefer, CEO, Sail Biomedicines 🔹 Lovisa Afzelius, Co-founder and CEO, Metaphore Biotechnologies 🔹 Christopher Austin, CEO, Vesalius Therapeutics 🔹 Jason Gardner, CEO, Ampersand Biomedicines 🔹 Jason Park, CEO, Empress Therapeutics 🔹 Eric Shaff, CEO, Seres Therapeutics 🔹 Lovisa Afzelius, Co-founder and CEO, Apriori Bio 🔹 Margo Georgiadis, Co-founder and CEO, Montai Health 🔹 Adrian Gottschalk, CEO, Foghorn Therapeutics Inc. 🔹 Steve Hahn, CEO, Harbinger Health 🔹 Mahesh Karande, President and CEO, Omega Therapeutics 🔹 Jacob Rubens, President, Quotient Therapeutics 🔹 Michelle Werner, CEO, Alltrna #FlagshipJPM #JPM24 #JPM2024
-
Listen to CEO, Volker Herrmann, MD, who sat down last week with Flagship Pioneering at #jpm2024 to discuss Network Medicines, our partnerships, and other exciting things on the horizon for Sonata in 2024. #biotech https://lnkd.in/gupczZne
-
Sonata is proud to be #FlagshipFounded and part of an ecosystem of pioneering bioplatforms continuously evolving how to best innovate for patients and the planet. Read CEO Noubar Afeyan's annual newsletter here: #FlagshipFounded
In Flagship’s 2024 Annual Letter, Founder & CEO Noubar Afeyan reflects on navigating the polycrisis and how to harness uncertainty and disequilibrium to propel progress and make the impossible possible. https://lnkd.in/ez-KuWxi #WeAreFlagship #FlagshipJPM #JPM24
Navigating the Polycrisis by Noubar Afeyan, Flagship Founder & CEO
flagshippioneering.com